


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A pyrrolo[3,2-d]pyrimidine compound represented by Formula (I) or a pharmaceutically acceptable salt thereof



wherein,

X represents an oxygen atom or a sulfur atom,

n represents 0, 1, or 2,

A represents a nitrogen atom

G^0 represents a divalent group of substituted or unsubstituted benzene, furan, thiophene, pyrrole, isoxazole, cyclopentane or cyclohexane, or a divalent group represented by $-CR^1R^2-$ wherein R^1 and R^2 , which may be the same or different, represent a hydrogen atom, a substituted or unsubstituted aliphatic hydrocarbon group having one to four carbons, or $NR^{10}R^{20}$ in which R^{10} and R^{20} , which may be the same or different, represent a hydrogen atom, a substituted or unsubstituted aliphatic hydrocarbon group having one to four carbons, or an optionally substituted group in which R^1 and R^2 bind to each other and form a 3- to 7-membered ring together with a carbon atom (C in $-CR^1R^2-$) to which R^1 and R^2 are bound, provided that R^1 and R^2 are not $NR^{10}R^{20}$ at the same time,

G^1 represents a binding hand which is a single bond, or a group that binds A to which G^1 binds and R^3 in the form of $A-C(=O)-O-R^3$, $A-C(=O)-R^3$, $A-C(=O)-NR^{30}-R^3$, $A-C(=S)-NR^{31}-R^3$,

A-C(=O)-NR³²-S(=O)₂-R³, or A-S(=O)₂-R³ wherein R³⁰ to R³¹ and R³² represent, independently from one another, a hydrogen atom or a substituted or unsubstituted aliphatic hydrocarbon group having one to four carbons,

R³ represents a group selected from the following 1)-5):

- 1) a single bond,
- 2) a substituted or unsubstituted alicyclic hydrocarbon group having three to eight carbons wherein substituents are one or more substituents selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxy group, an optionally substituted alkoxy group having one to seven carbons, an aryloxy group having six to ten carbons, an aralkoxy group having seven to nine carbons, an acyloxy group having two to seven carbons, an oxo group, an alkylsulfonyloxy group having one to six carbons, an optionally substituted acyl group having two to seven carbons, a carboxyl group, an alkoxy carbonyl group having two to seven carbons, a carbamoyl group, an optionally substituted alkyl carbamoyl group having two to seven carbons, an amino group, an optionally substituted alkylamino group having one to six carbons, an optionally substituted acylamino group having two to seven carbons, an alkoxy carbonyl amino group having two to eight carbons, an alkylsulfonyl amino group having one to six carbons, a cyano group, a nitro group, an alkylthio group having one to six carbons, an alkylsulfinyl group having one to six carbons, an alkylsulfonyl group having one to six carbons, a sulfamoyl group, an alkylaminosulfonyl group having one to six carbons, a sulpho group, an optionally substituted alicyclic hydrocarbon group having three to six carbons, and an optionally substituted aliphatic hydrocarbon group having one to six carbons,
- 3) a substituted or unsubstituted aromatic hydrocarbon group having six to 14 carbons wherein substituents are one or more substituents selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxy group, an optionally substituted alkoxy group having one to seven carbons, an aryloxy group having six to ten carbons, an aralkoxy group having seven to nine carbons, an acyloxy group having two to seven carbons, an oxo group, an alkylsulfonyloxy group having one to six carbons, an optionally substituted acyl group having two to seven carbons, a carboxyl group, an alkoxy carbonyl group having two to seven carbons, a carbamoyl group, an optionally substituted alkyl carbamoyl group having two to seven carbons, an amino group, an optionally substituted alkylamino group having one to six

carbons, an optionally substituted acylamino group having two to seven carbons, an alkoxy carbonylamino group having two to eight carbons, an alkylsulfonylamino group having one to six carbons, a cyano group, a nitro group, an alkylthio group having one to six carbons, an alkylsulfinyl group having one to six carbons, an alkylsulfonyl group having one to six carbons, a sulfamoyl group, an alkylaminosulfonyl group having one to six carbons, a sulpho group, an optionally substituted alicyclic hydrocarbon group having three to six carbons, and an optionally substituted aliphatic hydrocarbon group having one to six carbons,

4) a substituted or unsubstituted heterocyclic group containing, in the ring, one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom wherein substituents are one or more substituents selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxy group, an optionally substituted alkoxy group having one to seven carbons, an aryloxy group having six to ten carbons, an aralkoxy group having seven to nine carbons, an acyloxy group having two to seven carbons, an oxo group, an alkylsulfonyloxy group having one to six carbons, an optionally substituted acyl group having two to seven carbons, a carboxyl group, an alkoxy carbonyl group having two to seven carbons, a carbamoyl group, an optionally substituted alkylcarbamoyl group having two to seven carbons, an amino group, an optionally substituted alkylamino group having one to six carbons, an optionally substituted acylamino group having two to seven carbons, an alkoxy carbonylamino group having two to eight carbons, an alkylsulfonylamino group having one to six carbons, a cyano group, a nitro group, an alkylthio group having one to six carbons, an alkylsulfinyl group having one to six carbons, an alkylsulfonyl group having one to six carbons, a sulfamoyl group, an alkylaminosulfonyl group having one to six carbons, a sulpho group, an optionally substituted alicyclic hydrocarbon group having three to six carbons, and an optionally substituted aliphatic hydrocarbon group having one to six carbons,

5) a substituted or unsubstituted aliphatic hydrocarbon group having one to ten carbons wherein substituents are one or more substituents selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxy group, an optionally substituted alkoxy group having one to seven carbons, an optionally substituted phenylalkoxy group having seven to ten carbons, an alkoxy group having one to four carbons substituted with an optionally substituted heterocyclic group containing, in the ring, one to four atoms selected from the group

consisting of an oxygen atom, a nitrogen atom, and a sulfur atom), an aryloxy group having six to ten carbons, an acyloxy group having two to seven carbons, an oxo group, an alkylsulfonyloxy group having one to six carbons, an optionally substituted acyl group having two to seven carbons, a carboxyl group, an alkoxy carbonyl group having two to seven carbons, a carbamoyl group, an optionally substituted alkyl carbamoyl group having two to seven carbons, an amino group, an optionally substituted alkylamino group having one to six carbons, an optionally substituted acylamino group having two to seven carbons, an alkoxy carbonylamino group having two to eight carbons, an alkylsulfonylamino group having one to six carbons, a cyano group, a nitro group, an alkylthio group having one to six carbons, an alkylsulfinyl group having one to six carbons, an alkylsulfonyl group having one to six carbons, a sulfamoyl group, an alkylaminosulfonyl group having one to six carbons, a sulpho group, an optionally substituted alicyclic hydrocarbon group having three to six carbons, an optionally substituted aromatic hydrocarbon group having six to 14 carbons, and an optionally substituted heterocyclic group containing, in the ring, one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom,

R⁴ represents a group selected from the following 1)-4):

- 1) a single bond,
- 2) a substituted or unsubstituted alicyclic hydrocarbon group having three to eight carbons wherein substituents are one or more substituents selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxy group, an optionally substituted alkoxy group having one to seven carbons, an aryloxy group having six to ten carbons, an aralkoxy group having seven to nine carbons, an acyloxy group having two to seven carbons, an oxo group, an alkylsulfonyloxy group having one to six carbons, an optionally substituted acyl group having two to seven carbons, a carboxyl group, an alkoxy carbonyl group having two to seven carbons, a carbamoyl group, an optionally substituted alkyl carbamoyl group having two to seven carbons, an amino group, an optionally substituted alkylamino group having one to six carbons, an optionally substituted acylamino group having two to seven carbons, an alkoxy carbonylamino group having two to eight carbons, an alkylsulfonylamino group having one to six carbons, a cyano group, a nitro group, an alkylthio group having one to six carbons, an alkylsulfinyl group having one to six carbons, an alkylsulfonyl group having one to six carbons,

a sulfamoyl group, an alkylaminosulfonyl group having one to six carbons, a sulpho group, an optionally substituted alicyclic hydrocarbon group having three to six carbons, and an optionally substituted aliphatic hydrocarbon group having one to six carbons,

3) a substituted or unsubstituted aromatic hydrocarbon group having six to 14 carbons wherein substituents are one or more substituents selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxy group, an optionally substituted alkoxy group having one to seven carbons, an aryloxy group having six to ten carbons, an aralkoxy group having seven to nine carbons, an acyloxy group having two to seven carbons, an oxo group, an alkylsulfonyloxy group having one to six carbons, an optionally substituted acyl group having two to seven carbons, a carboxyl group, an alkoxy carbonyl group having two to seven carbons, a carbamoyl group, an optionally substituted alkylcarbamoyl group having two to seven carbons, an amino group, an optionally substituted alkylamino group having one to six carbons, an optionally substituted acylamino group having two to seven carbons, an alkoxy carbonylamino group having two to eight carbons, an alkylsulfonylamino group having one to six carbons, a cyano group, a nitro group, an alkylthio group having one to six carbons, an alkylsulfinyl group having one to six carbons, an alkylsulfonyl group having one to six carbons, a sulfamoyl group, an alkylaminosulfonyl group having one to six carbons, a sulpho group, an optionally substituted alicyclic hydrocarbon group having three to six carbons, and an optionally substituted aliphatic hydrocarbon group having one to six carbons,

4) a substituted or unsubstituted heterocyclic group containing, in the ring, one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom wherein substituents are one or more substituents selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxy group, an optionally substituted alkoxy group having one to seven carbons, an aryloxy group having six to ten carbons, an aralkoxy group having seven to nine carbons, an acyloxy group having two to seven carbons, an oxo group, an alkylsulfonyloxy group having one to six carbons, an optionally substituted acyl group having two to seven carbons, a carboxyl group, an alkoxy carbonyl group having two to seven carbons, a carbamoyl group, an optionally substituted alkylcarbamoyl group having two to seven carbons, an amino group, an optionally substituted alkylamino group having one to six carbons, an optionally substituted acylamino group having two to seven carbons, an

alkoxycarbonylamino group having two to eight carbons, an alkylsulfonylamino group having one to six carbons, a cyano group, a nitro group, an alkylthio group having one to six carbons, an alkylsulfinyl group having one to six carbons, an alkylsulfonyl group having one to six carbons, a sulfamoyl group, an alkylaminosulfonyl group having one to six carbons, a sulpho group, an optionally substituted alicyclic hydrocarbon group having three to six carbons, and an optionally substituted aliphatic hydrocarbon group having one to six carbons,

G^2 represents $-C(=O)-OH$, $-C(=O)-NH-OH$, $-S(=O)_2-OH$, or a 5-tetrazolyl group.

2. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A represents a nitrogen atom.

3. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein G^0 is a divalent group represented by $-CR^1R^2-$.

4. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein G^0 is a divalent group represented by $-CR^1R^2-$ wherein R^1 and R^2 , which may be the same or different, are a hydrogen atom or an optionally substituted aliphatic hydrocarbon group having one to four carbons, or R^1 and R^2 bind to each other and form a cyclopropane ring together with a carbon atom to which R^1 and R^2 are bound.

5. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein G^0 is a divalent group represented by $-CR^1R^2-$ wherein R^1 and R^2 , which may be the same or different, are a hydrogen atom or a methyl group, or R^1 and R^2 bind to each other and form a cyclopropane ring together with a carbon atom to which R^1 and R^2 are bound.

6. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein G^0 is a divalent group represented

by -CR¹R²- wherein R¹ is an optionally substituted aliphatic hydrocarbon group having one to four carbons and R² is a hydrogen atom.

7. **(previously presented):** A pyrrolo[3,2-d]pyrimidine compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein G⁰ is a divalent group represented by -CR¹R²- wherein R¹ is a methyl group and R² is a hydrogen atom.

8. **(previously presented):** A pyrrolo[3,2-d]pyrimidine compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein G⁰ is a divalent group represented by -CR¹R²- wherein each of R¹ and R² is a methyl group, or R¹ and R² bind to each other and form a cyclopropane ring together with a carbon atom to which R¹ and R² are bound.

9. **(withdrawn):** A pyrrolo[3,2-d]pyrimidine compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein G⁰ is a divalent group of an optionally substituted benzene, furan, thiophene, pyrrole, isoxazole, cyclopentane or cyclohexane, and G⁰, (CH₂)_n, A, -(CH₂)₂-, and a nitrogen atom and a carbon atom in the pyrrole ring of the pyrrolopyrimidine ring form a 10- to 12-membered bicyclic structure.

10. **(withdrawn):** A pyrrolo[3,2-d]pyrimidine compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein G⁰ is a divalent group of an optionally substituted benzene, and G⁰, (CH₂)_n, A, -(CH₂)₂-, and a nitrogen atom and a carbon atom in the pyrrole ring of the pyrrolopyrimidine ring form a 10- to 12-membered bicyclic structure.

11. **(withdrawn):** A pyrrolo[3,2-d]pyrimidine compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein G⁰ is a divalent group of benzene, furan, thiophene, pyrrole, isoxazole, cyclopentane or cyclohexane, and G⁰, (CH₂)_n, A, -(CH₂)₂-, and a nitrogen atom and a carbon atom in the pyrrole ring of the pyrrolopyrimidine ring form a 10- to 12-membered bicyclic structure, and said bicyclic structure has 3-5 substituents.

12. **(withdrawn):** A pyrrolo[3,2-d]pyrimidine compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein G^0 is a divalent group of an optionally substituted isoxazole, and G^0 , $(CH_2)_n$, A, $-(CH_2)_2$, and a nitrogen atom and a carbon atom in the pyrrole ring of the pyrrolopyrimidine ring form a 10- to 12-membered bicyclic structure.

13. **(previously presented):** A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein R^3 is a divalent group of an optionally substituted, saturated aliphatic hydrocarbon group having five to ten carbons, an optionally substituted alicyclic hydrocarbon group having five to eight carbons, an optionally substituted aromatic hydrocarbon group having six to ten carbons, or an optionally substituted heterocyclic group containing one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom.

14. **(previously presented):** A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein R^3 is a divalent group of an optionally substituted heterocyclic group (containing, in the ring, one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom).

15. **(previously presented):** A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein $A-G^1-R^3$ represents a group that binds in the form of $A-C(=O)-NH-R^3$, $A-C(=S)-NH-R^3$, or $A-C(=O)-NH-S(=O)_2-R^3$, and R^3 is a divalent group of an optionally substituted aliphatic hydrocarbon group having one to ten carbons, an optionally substituted alicyclic hydrocarbon group having three to eight carbons, an optionally substituted aromatic hydrocarbon group having six to ten carbons, or an optionally substituted heterocyclic group containing, in the ring, one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom.

16. **(previously presented):** A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein $A-G^1-R^3$ represents a group that binds in the form of $A-C(=O)-NH-R^3$ or $A-C(=S)-NH-R^3$, and R^3 is a

divalent group of an optionally substituted aliphatic hydrocarbon group having one to ten carbons, an optionally substituted alicyclic hydrocarbon group having three to eight carbons, an optionally substituted aromatic hydrocarbon group having six to ten carbons, or an optionally substituted heterocyclic group containing, in the ring, one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom.

17. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein A-G¹-R³ represents a group that binds in the form of A-C(=O)-NH-R³, and R³ is a divalent group of an optionally substituted aliphatic hydrocarbon group having one to ten carbons, an optionally substituted alicyclic hydrocarbon group having three to eight carbons, an optionally substituted aromatic hydrocarbon group having six to ten carbons, or an optionally substituted heterocyclic group containing, in the ring, one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom.

18. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein A-G¹-R³ represents a group that binds in the form of A-C(=O)-NH-R³, and R³ is a divalent group of an optionally substituted alkane having five to ten carbons, an optionally substituted alicyclic hydrocarbon group having five to eight carbons, an optionally substituted aromatic hydrocarbon group having six to ten carbons, or an optionally substituted heterocyclic group (containing, in the ring, one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom).

19. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein A-G¹-R³ represents a group that binds in the form of A-C(=O)-NH-R³, and R³ is a divalent group of an optionally substituted heterocyclic group containing, in the ring, one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom.

20. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein A-G¹-R³ represents a group that binds in the form of A-C(=O)-R³, A-C(=O)-NH-R³, or A-C(=S)-NH-R³, and G² represents any of -C(=O)-OH, -C(=O)-NH-OH, -S(=O)₂-OH, and 5-tetrazolyl group.

21. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein A-G¹-R³ represents a group that binds in the form of A-C(=O)-R³, A-C(=O)-NH-R³, or A-C(=S)-NH-R³, and G² represents -C(=O)-OH.

22. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein A-G¹-R³ represents a group that binds in the form of A-C(=O)-NH-R³, and G² represents any of -C(=O)-OH, -C(=O)-NH-OH, -S(=O)₂-OH, and 5-tetrazolyl group.

23. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein A-G¹-R³ represents a group that binds in the form of A-C(=O)-NH-R³, and G² represents -C(=O)-OH.

24. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein -G¹- represents a single bond, and R³ is a divalent group of an alkane having two to six carbons substituted with an optionally substituted alkoxy group having one to four carbons, an optionally substituted phenylalkoxy group having seven to ten carbons, or an optionally substituted aryloxy group having six to ten carbons.

25. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein -G¹- represents a single bond, and R³ is a divalent group of an alkane having two to four carbons substituted with an optionally substituted alkoxy group having one to four carbons.

26. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein -G¹- represents a single bond, and R³ is a divalent group of an alkane having two to four carbons substituted with a phenylalkoxy group having seven to ten carbons.

27. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein -G¹- represents a single bond, and R³ is a divalent group of an alkane having two to four carbons substituted with an alkoxy group having one to four carbons substituted with an optionally substituted heterocyclic group containing, in the ring, one to four atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom.

28. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein -G¹- represents a single bond, and R³ is a divalent group of an alkane having two to four carbons substituted with an phenoxy group.

29. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein -G¹- represents a single bond, and R³ is a divalent group of an alkane having two to four carbons substituted with an optionally substituted benzyloxy group.

30. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein -G¹- represents a single bond, and R³ represents -CH₂-, and R⁴ is a divalent group of an aromatic hydrocarbon group having six to ten carbons said group having G² other than a hydrogen atom or a substituent at a carbon atom of R⁴ at a position adjacent to the carbon atom of R⁴ at which -R³- binds, or a heterocyclic group containing, in the ring, one to four atoms selected from the group consisting

of an oxygen atom, a nitrogen atom, and a sulfur atom) having G² other than a hydrogen atom or a substituent at an atom at a position adjacent to the carbon atom of R⁴ at which -R³- binds.

31. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein X is an oxygen atom.

32. (previously presented): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims 2 to 8 or a pharmaceutically acceptable salt thereof, wherein X is a sulfur atom.

33. (currently amended): A pyrrolo[3,2-d]pyrimidine compound according to any one of claims ~~2-to-301 to 8~~ or a pharmaceutically acceptable salt thereof, wherein G⁰ is a divalent group represented by -CR¹R²-, wherein R¹ and R², which may be the same or different, are a hydrogen atom or a methyl group, n represents 1, and X is a sulfur atom.

34. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A represents CH.

35. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 34 or a pharmaceutically acceptable salt thereof, wherein G⁰ is a divalent group represented by -CR¹R²-, wherein R¹ and R², which may be the same or different, are a hydrogen atom or a substituted or unsubstituted aliphatic hydrocarbon group having one to four carbons, or R¹ and R² bind to each other and form a cyclopropane ring together with a carbon atom to which R¹ and R² are bound.

36. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 34 or a pharmaceutically acceptable salt thereof, wherein G⁰ is a divalent group represented by -CR¹R²-, wherein R¹ and R², which may be the same or different, are a hydrogen atom or a methyl group, or R¹ and R² bind to each other and form a cyclopropane ring together with a carbon atom to which R¹ and R² are bound.

37. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 34 or a pharmaceutically acceptable salt thereof, wherein G^0 is a divalent group represented by $-CR^1R^2-$, wherein R^1 is a substituted or unsubstituted aliphatic hydrocarbon group having one to four carbons and R^2 is a hydrogen atom.

38. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 34 or a pharmaceutically acceptable salt thereof, wherein G^0 is a divalent group represented by $-CR^1R^2-$, wherein R^1 is a methyl group and R^2 is a hydrogen atom.

39. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 34 or a pharmaceutically acceptable salt thereof, wherein G^0 is a divalent group represented by $-CR^1R^2-$, wherein both of R^1 and R^2 are a methyl group, or R^1 and R^2 bind to each other and form a cyclopropane ring together with a carbon atom to which R^1 and R^2 are bound.

40. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 34 or a pharmaceutically acceptable salt thereof, wherein G^0 represents a divalent group of an optionally substituted benzene, furan, thiophene, pyrrole, isoxazole, cyclopentane or cyclohexane, and G^0 , $(CH_2)_n$, A, $-(CH_2)_2$, and a nitrogen atom and a carbon atom in the pyrrole ring of the pyrrolopyrimidine ring form a 10- to 12-membered bicyclic structure.

41. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 34 or a pharmaceutically acceptable salt thereof, wherein G^0 represents a divalent group of optionally substituted benzene, and G^0 , $(CH_2)_n$, A, $-(CH_2)_2$, and a nitrogen atom and a carbon atom in the pyrrole ring of the pyrrolopyrimidine ring form a 10- to 12-membered bicyclic structure.

42. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 34 or a pharmaceutically acceptable salt thereof, wherein G^0 represents a divalent group of a substituted benzene, furan, thiophene, pyrrole, isoxazole, cyclopentane or cyclohexane, and G^0 , $(CH_2)_n$, A, -

$(\text{CH}_2)_2$ -, and a nitrogen atom and a carbon atom in the pyrrole ring of the pyrrolopyrimidine ring form a 10- to 12-membered bicyclic structure and said bicyclic structure has 3-5 substituents.

43. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 34 or a pharmaceutically acceptable salt thereof, wherein G^0 represents a divalent group of an optionally substituted isoxazole, and G^0 , $(\text{CH}_2)_n$, A, $-(\text{CH}_2)_2$ -, and a nitrogen atom and a carbon atom in the pyrrole ring of the pyrrolopyrimidine ring form a 10- to 12-membered bicyclic structure.


44. (canceled).

45. (canceled).

46. (canceled).

47. (canceled).

48. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound represented by Formula (II)



In Formula (II), n, A, R^3 , R^4 , G^0 , G^1 , and G^2 are as defined for Formula (I). X^1 represents a chlorine atom, a bromine atom, an iodine atom, or an alkyl or arylsulfonyl group having one to eight carbons that may be substituted with a fluorine atom, a chlorine atom, or a bromine atom.

49. (withdrawn): A pyrrolo[3,2-d]pyrimidine compound according to claim 48 wherein X¹ is a chlorine atom or a trifluoromethylsulfonyloxy group.